Thursday, October 11, 2012

2012 AASLD- What To Expect From Jules Levin

Updates From Executive Director of NATAP - National AIDS Treatment Advocacy Project: Jules Levin

HCV - Whats Coming
From Jules: Next month in November the big annual liver meeting AASLD will take place, where we will see the latest new data on new HCV therapies. We already know from the European EASL meeting held in April 2012 that interferon-free therapy regimens composed of 2-4 new oral drugs will be developed. There are 6 new HCV drugs in phase 3 now: 3 new once-daily protease inhibitors, a potent first-in-class NS5A inhibitor, a potent first-in-class nucleotide, and the new PegLambda. In addition right behind this in phase 2b & 2a are many new HCV oral drugs including potent protease inhibitors, NS5A inhibitors, non-nucleoside polymerase inhibitors, a nucleoside, as well as a newly developed 2nd nucleotide....

HCV Screening/Baby Boomers, a misleading characterization
From Jules Levin: The anemic federal response to HCV is what the federal govt does, they don't respond to major issues - unless they are forced to, they don't respond unless it is politically necessary. They were forced to respond to HIV, not to HCV. The focus on baby boomers screening for HCV is misleading if you have come to think that screening baby boomers is the only or even the major focus.....

More Hep C Articles...

No comments:

Post a Comment